Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody

Xianglin Wu, Malayannan Subramaniam, Vivian Negron, Muzaffer Cicek, Carol Reynolds, Wilma L. Lingle, Matthew Philip Goetz, James N. Ingle, Thomas C. Spelsberg, John R Hawse

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The role of estrogen receptor alpha (ERα) in breast cancer has been studied extensively, and its protein expression is prognostic and a primary determinant of endocrine sensitivity. However, much less is known about the role of ERβ and its relevance remains unclear due to the publication of conflicting reports. Here, we provide evidence that much of this controversy may be explained by variability in antibody sensitivity and specificity and describe the development, characterization, and potential applications of a novel monoclonal antibody targeting full-length human ERβ and its splice variant forms. Specifically, we demonstrate that a number of commercially available ERβ antibodies are insensitive for ERβ and exhibit significant cross-reaction with ERα. However, our newly developed MC10 ERβ antibody is shown to be highly specific and sensitive for detection of full-length ERβ and its variant forms. Strong and variable staining patterns for endogenous levels of ERβ protein were detected in normal human tissues and breast tumors using the MC10 antibody. Importantly, ERβ was shown to be expressed in a limited cohort of both ERα positive and ERα negative breast tumors. Taken together, these data demonstrate that the use of poorly validated ERβ antibodies is likely to explain much of the controversy in the field with regard to the biological relevance of ERβ in breast cancer. The use of the MC10 antibody, in combination with highly specific antibodies targeting only full-length ERβ, is likely to provide additional discriminatory features in breast cancers that may be useful in predicting response to therapy.

Original languageEnglish (US)
Pages (from-to)711-723
Number of pages13
JournalJournal of Cellular Biochemistry
Volume113
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Estrogen Receptor beta
Estrogen Receptor alpha
Monoclonal Antibodies
Antibodies
Breast Neoplasms
Tumors
Antibody Specificity
Cross Reactions

Keywords

  • Antibody
  • Breast cancer
  • Estrogen receptor
  • Estrogen receptor beta

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody. / Wu, Xianglin; Subramaniam, Malayannan; Negron, Vivian; Cicek, Muzaffer; Reynolds, Carol; Lingle, Wilma L.; Goetz, Matthew Philip; Ingle, James N.; Spelsberg, Thomas C.; Hawse, John R.

In: Journal of Cellular Biochemistry, Vol. 113, No. 2, 02.2012, p. 711-723.

Research output: Contribution to journalArticle

Wu, X, Subramaniam, M, Negron, V, Cicek, M, Reynolds, C, Lingle, WL, Goetz, MP, Ingle, JN, Spelsberg, TC & Hawse, JR 2012, 'Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody', Journal of Cellular Biochemistry, vol. 113, no. 2, pp. 711-723. https://doi.org/10.1002/jcb.23443
Wu, Xianglin ; Subramaniam, Malayannan ; Negron, Vivian ; Cicek, Muzaffer ; Reynolds, Carol ; Lingle, Wilma L. ; Goetz, Matthew Philip ; Ingle, James N. ; Spelsberg, Thomas C. ; Hawse, John R. / Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody. In: Journal of Cellular Biochemistry. 2012 ; Vol. 113, No. 2. pp. 711-723.
@article{bacff45a86364723b726493a437f94a8,
title = "Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody",
abstract = "The role of estrogen receptor alpha (ERα) in breast cancer has been studied extensively, and its protein expression is prognostic and a primary determinant of endocrine sensitivity. However, much less is known about the role of ERβ and its relevance remains unclear due to the publication of conflicting reports. Here, we provide evidence that much of this controversy may be explained by variability in antibody sensitivity and specificity and describe the development, characterization, and potential applications of a novel monoclonal antibody targeting full-length human ERβ and its splice variant forms. Specifically, we demonstrate that a number of commercially available ERβ antibodies are insensitive for ERβ and exhibit significant cross-reaction with ERα. However, our newly developed MC10 ERβ antibody is shown to be highly specific and sensitive for detection of full-length ERβ and its variant forms. Strong and variable staining patterns for endogenous levels of ERβ protein were detected in normal human tissues and breast tumors using the MC10 antibody. Importantly, ERβ was shown to be expressed in a limited cohort of both ERα positive and ERα negative breast tumors. Taken together, these data demonstrate that the use of poorly validated ERβ antibodies is likely to explain much of the controversy in the field with regard to the biological relevance of ERβ in breast cancer. The use of the MC10 antibody, in combination with highly specific antibodies targeting only full-length ERβ, is likely to provide additional discriminatory features in breast cancers that may be useful in predicting response to therapy.",
keywords = "Antibody, Breast cancer, Estrogen receptor, Estrogen receptor beta",
author = "Xianglin Wu and Malayannan Subramaniam and Vivian Negron and Muzaffer Cicek and Carol Reynolds and Lingle, {Wilma L.} and Goetz, {Matthew Philip} and Ingle, {James N.} and Spelsberg, {Thomas C.} and Hawse, {John R}",
year = "2012",
month = "2",
doi = "10.1002/jcb.23443",
language = "English (US)",
volume = "113",
pages = "711--723",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody

AU - Wu, Xianglin

AU - Subramaniam, Malayannan

AU - Negron, Vivian

AU - Cicek, Muzaffer

AU - Reynolds, Carol

AU - Lingle, Wilma L.

AU - Goetz, Matthew Philip

AU - Ingle, James N.

AU - Spelsberg, Thomas C.

AU - Hawse, John R

PY - 2012/2

Y1 - 2012/2

N2 - The role of estrogen receptor alpha (ERα) in breast cancer has been studied extensively, and its protein expression is prognostic and a primary determinant of endocrine sensitivity. However, much less is known about the role of ERβ and its relevance remains unclear due to the publication of conflicting reports. Here, we provide evidence that much of this controversy may be explained by variability in antibody sensitivity and specificity and describe the development, characterization, and potential applications of a novel monoclonal antibody targeting full-length human ERβ and its splice variant forms. Specifically, we demonstrate that a number of commercially available ERβ antibodies are insensitive for ERβ and exhibit significant cross-reaction with ERα. However, our newly developed MC10 ERβ antibody is shown to be highly specific and sensitive for detection of full-length ERβ and its variant forms. Strong and variable staining patterns for endogenous levels of ERβ protein were detected in normal human tissues and breast tumors using the MC10 antibody. Importantly, ERβ was shown to be expressed in a limited cohort of both ERα positive and ERα negative breast tumors. Taken together, these data demonstrate that the use of poorly validated ERβ antibodies is likely to explain much of the controversy in the field with regard to the biological relevance of ERβ in breast cancer. The use of the MC10 antibody, in combination with highly specific antibodies targeting only full-length ERβ, is likely to provide additional discriminatory features in breast cancers that may be useful in predicting response to therapy.

AB - The role of estrogen receptor alpha (ERα) in breast cancer has been studied extensively, and its protein expression is prognostic and a primary determinant of endocrine sensitivity. However, much less is known about the role of ERβ and its relevance remains unclear due to the publication of conflicting reports. Here, we provide evidence that much of this controversy may be explained by variability in antibody sensitivity and specificity and describe the development, characterization, and potential applications of a novel monoclonal antibody targeting full-length human ERβ and its splice variant forms. Specifically, we demonstrate that a number of commercially available ERβ antibodies are insensitive for ERβ and exhibit significant cross-reaction with ERα. However, our newly developed MC10 ERβ antibody is shown to be highly specific and sensitive for detection of full-length ERβ and its variant forms. Strong and variable staining patterns for endogenous levels of ERβ protein were detected in normal human tissues and breast tumors using the MC10 antibody. Importantly, ERβ was shown to be expressed in a limited cohort of both ERα positive and ERα negative breast tumors. Taken together, these data demonstrate that the use of poorly validated ERβ antibodies is likely to explain much of the controversy in the field with regard to the biological relevance of ERβ in breast cancer. The use of the MC10 antibody, in combination with highly specific antibodies targeting only full-length ERβ, is likely to provide additional discriminatory features in breast cancers that may be useful in predicting response to therapy.

KW - Antibody

KW - Breast cancer

KW - Estrogen receptor

KW - Estrogen receptor beta

UR - http://www.scopus.com/inward/record.url?scp=84862932561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862932561&partnerID=8YFLogxK

U2 - 10.1002/jcb.23443

DO - 10.1002/jcb.23443

M3 - Article

C2 - 22095450

AN - SCOPUS:84862932561

VL - 113

SP - 711

EP - 723

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 2

ER -